Cerevel Therapeutics Holdings, Inc. - CERE STOCK NEWS

Cerevel Therapeutics (Nasdaq: CERE) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022. CEO Tony Coles will take part in a fireside chat at 9:20 AM ET. Investors can access the live webcast via the company's website, with a replay available afterward. Cerevel, based in Cambridge, specializes in neuroscience diseases and has a diversified pipeline, including five clinical-stage therapies for conditions such as Parkinson’s and schizophrenia.

Cerevel Therapeutics Holdings, Inc. (CERE) announced the pricing of a public offering of 7,250,000 shares at $35.00 per share, raising approximately $253.8 million. The offering is set to close on August 16, 2022. Additionally, Cerevel priced $300 million in convertible senior notes due 2027 in a concurrent private placement. Net proceeds from both offerings are expected to support the development of emraclidine and other pipeline programs, with $238.3 million estimated from common stock and $291.1 million from the notes.

Cerevel Therapeutics has priced a private offering of $300 million in 2.50% convertible senior notes due 2027, with an additional $45 million option for buyers. The notes, offering a conversion rate of 21.5633 shares per $1,000 principal, will mature on August 15, 2027, with semi-annual interest payments starting February 15, 2023. Concurrently, Cerevel is offering 7,250,000 shares of common stock at $35 per share, expecting net proceeds of approximately $238.3 million. Proceeds from both offerings will support the development of emraclidine and its pipeline programs.

Cerevel Therapeutics Holdings has announced a public offering of $250 million in common stock, with a potential additional $37.5 million available through underwriters. Concurrently, the company will offer $250 million in convertible senior notes due 2027. Cerevel plans to use the proceeds for the development of emraclidine and other programs, including pre-commercial planning for tavapadon. The offering is subject to market conditions, and all shares in the stock offering will be sold by Cerevel.

Cerevel Therapeutics announced a private offering of $250 million in convertible senior notes due 2027 to qualified institutional buyers. The offering includes an option for purchasers to buy an additional $37.5 million. Interest will be payable semi-annually, and noteholders can convert notes into cash or shares. Concurrently, Cerevel is offering $250 million in common stock with a similar option for underwriters. Proceeds will support the development of emraclidine and other pipeline programs, as well as general corporate purposes.

Cerevel Therapeutics reported its Q2 2022 financial results and provided updates on its pipeline, emphasizing a commitment to neuroscience therapies. The company has initiated two Phase 2 trials for emraclidine in schizophrenia, with data expected in 1H 2024. Cerevel maintains a healthy cash position of $531M, projected to support operations through 2024. Additionally, the company is advancing its drug candidates, including darigabat for epilepsy and panic disorder, and tavapadon for Parkinson’s disease. The total R&D expenditure significantly rose to $72.5M for Q2.

Cerevel Therapeutics (Nasdaq: CERE) announced it will release its second quarter 2022 financial results on August 1, 2022, before the U.S. markets open. A conference call will follow at 8:00 a.m. ET, where management will discuss the results and recent business updates. Investors can register for the call via a provided link. Cerevel, focused on neuroscience disease treatments, has a pipeline that includes five clinical-stage therapies for conditions like Parkinson’s and schizophrenia.

Cerevel Therapeutics (Nasdaq: CERE) has appointed Suneet Varma as a new board member, succeeding Morris Birnbaum, who is retiring. Varma, currently Global President of Rare Diseases at Pfizer, brings extensive experience in commercial success and leadership. He aims to support Cerevel’s mission to advance treatments for neuroscience diseases. Dr. Birnbaum, a founding board member since 2018, significantly contributed to the company’s progress. The leadership change is expected to enhance Cerevel's capabilities in tackling complex neurological conditions.

Cerevel Therapeutics, listed on Nasdaq under the ticker CERE, announced that its chairperson and CEO, Tony Coles, M.D., will speak at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 am ET. The event will feature a live webcast available on the company's investor relations page, with a replay accessible after the event.

The company, focused on neuroscience diseases, has a pipeline of five clinical-stage therapies targeting conditions such as Parkinson's and schizophrenia. For more details, visit www.cerevel.com.